schizandrer a has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chong, CM; Guo, BJ; Hoi, PM; Lee, SM; Li, S; Sa, F; Zhang, LQ; Zhang, ZJ; Zheng, Y | 1 |
| Chen, T; Lee, SM; Li, C; Li, Y; Yi, X; Zheng, Y | 1 |
2 other study(ies) available for schizandrer a and Parkinson Disease
| Article | Year |
|---|---|
Discovery of novel anti-parkinsonian effect of schisantherin A in in vitro and in vivo.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Brain; Cell Line, Tumor; Cell Survival; Cyclic AMP Response Element-Binding Protein; Cyclooctanes; Dioxoles; Dopaminergic Neurons; Humans; Lignans; Male; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2015 |
Oral Delivery of a Nanocrystal Formulation of Schisantherin A with Improved Bioavailability and Brain Delivery for the Treatment of Parkinson's Disease.
Topics: Administration, Oral; Animals; Brain; Cyclooctanes; Dioxoles; Disease Models, Animal; Drug Compounding; Lignans; Male; Nanoparticles; Parkinson Disease; Rats, Sprague-Dawley; Zebrafish | 2016 |